中国の実証地域における糖尿病の予防と制御のための実現可能性と優先戦略

Jing Li^1,2, Jing Yang³, Jiayu Feng^1,2

¹Department of Health Statistics, School of Public Health, Shanxi Medical University, Jinzhong, China.

Global health action

|August 20, 2025

まとめ

効果的な資源配分には,糖尿病の予防と制御の措置を実行可能性によって優先することが不可欠です. 保健教育や早期介入などの重要な分野では,世界的な糖尿病対策の強化が必要です.

科学分野:

公衆衛生
慢性疾患の管理
健康政策

背景:

糖尿病は,2021年に5億3700万人の人に影響を及ぼし,世界的な健康上の重大な負担を担っています.
現存する予防と制御戦略は,実行可能性の制約のために実施の課題に直面しています.
効果的な糖尿病管理には介入の優先順位を決めることが不可欠です

研究の目的:

中国における糖尿病予防と制御対策を特定し,優先順位付けする.
実現可能性の観点からこれらの措置を評価する.
糖尿病への介入のためのリソースの割り当てをガイドする.

主な方法:

2021年初頭,中国の488の慢性疾患管理地域から専門家を対象にオンライン調査が行われました.
この調査では,糖尿病の予防と制御のための44の異なる措置の重要性と実行可能性が評価されました.
重要度・業績分析 (IPA) モデルを用いて,対策を優先度四半期に分類した.

主要な成果:

健康教育,地域活動,高リスクの発見/介入,医療保険/家庭医は"最優先" (重要度が高い,実現可能性が高い) と見なされた.
患者の管理と合併症のスクリーニングは"優先改善" (重要度が高い,実行可能性は低い) を要求します.
個人保健サービス,環境支援,糖質削減政策,共感染予防は"最優先事項" (重要度が低い,実行可能性が低い) と見なされた.

結論:

実現可能性に基づく糖尿病対策の優先順位は資源の利用を最適化します
この調査結果は中国の政策立案者にとって実行可能な勧告となる.
糖尿病の予防と制御を強化するために,優先度の高い措置を強化することが推奨されています.

キーワード:

重要性と業績の分析慢性疾患の予防健康政策の評価実施科学優先順位設定

さらに関連する動画

08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

関連する概念動画

01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

関連する実験動画